Stocks / MRVI vs PLSE

MRVI vs PLSE: Which Stock Is the Better Buy?

Maravai LifeSciences Holdings, Inc. and Pulse Biosciences, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.

MRVI is the larger company ($1.9B vs $1.8B). On the fundamentals, MRVI earns a higher net margin (-70.4% vs -20794.6%); MRVI has the stronger return on equity (-61.6% vs -90.2%). On the filings, PLSE carries fewer potential red flags (2 vs 3). Full numbers below — the stronger figure on each row is in green.

AI verdict — MRVI vs PLSE, read from the filings

The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.

 Maravai LifeSciences Holdings, Inc. (MRVI)Pulse Biosciences, Inc. (PLSE)
Market cap$1.9B$1.8B
Revenue (latest FY)$185.74M$350,000
Net income (latest FY)$-130.77M$-72.78M
Revenue growth (5y CAGR)-8.1%
Net margin-70.4%-20794.6%
Return on equity-61.6%-90.2%
P/E ratio
Dividend yield
Profitable years (of last 10)30
Positive free cash flowNoNo

Verify the comparison

Use the filing period and source shown by each tool before treating two figures as comparable.

Compare with another company:

See the full MRVI vs PLSE breakdown

Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.

Open MRVI's full financials →   Open PLSE's full financials →

More comparisons

Frequently asked questions

Which is bigger, MRVI or PLSE?

Maravai LifeSciences Holdings, Inc. is larger by market capitalization — $1.9B versus $1.8B.

Which grows faster, MRVI or PLSE?

Five-year growth data is not available for both companies.

Where does this data come from?

All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.

Keep exploring

MRVI fundamentals → · PLSE fundamentals → · All 1,500+ companies → · Free screener →